Browsing: Clinical Trials & R&D

Novo Nordisk GLP-1 drug fails in Alzheimer’s trials, impacting potential neurodegeneration treatment.

Bayer Asundexian trial results indicate potential for a new cardiovascular drug class, raising hopes after previous clinical setbacks.

Novo Nordisk’s GLP-1 drug semaglutide fails to slow cognitive decline in Alzheimer’s trials.

Novo Nordisk GLP-1 trials did not meet primary endpoints in Alzheimer’s studies, impacting potential neurodegeneration treatment.

J&J Alzheimer’s trial failure with posdinemab dims hopes for new treatments.

Novo Nordisk’s semaglutide failed in two Alzheimer’s trials, impacting stock by 10%.

Novo Nordisk Alzheimer’s trial with semaglutide fails to slow disease progression in over 3,800 patients.

Contineum MS trial failure leads to a significant share drop, affecting Johnson & Johnson’s interest.

Novo Nordisk is set to release pivotal Phase 3 data on semaglutide’s impact on Alzheimer’s, potentially reshaping treatment.

Novo Nordisk is set to reveal results of its semaglutide study for Alzheimer’s, potentially expanding its indications.